Calendario›REGN›Odronextamab · ATHENA-1

Odronextamab · ATHENA-1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Ensayo de REGENERON PHARMACEUTICALS, INC. en B-cell Non-Hodgkins Lymphoma (B-NHL) (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

107

previstos

Centros

20

Fin del objetivo primario

feb 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en abr 2023.

Qué mide

Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamab (From Cycle 2, Day 1 to Cycle 2, Day 21 (each induction cycle is 21 days)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05685173), actualizada en may 2026.